TY - JOUR
T1 - Pulmonary interstitial glycogenosis – A systematic analysis of new cases
AU - Seidl, E.
AU - Carlens, J.
AU - Reu, S.
AU - Wetzke, M.
AU - Ley-Zaporozhan, J.
AU - Brasch, F.
AU - Wesselak, T.
AU - Schams, A.
AU - Rauch, D.
AU - Schuch, L.
AU - Kappler, M.
AU - Schelstraete, P.
AU - Wolf, M.
AU - Stehling, F.
AU - Haarmann, E.
AU - Borensztajn, D.
AU - van de Loo, M.
AU - Rubak, S.
AU - Lex, C.
AU - Hinrichs, B.
AU - Reiter, K.
AU - Schwerk, N.
AU - Griese, M.
PY - 2018
Y1 - 2018
N2 - Background: Pulmonary interstitial glycogenosis (PIG) is a rare paediatric interstitial lung disease of unknown cause. The diagnosis can only be made by lung biopsy. Less than 100 cases have been reported. Clinical features, treatment and outcomes have rarely been assessed systematically in decent cohorts of patients. Methods: In this retrospective multicentre study, the clinical presentation, radiologic findings, pattern of lung biopsy, extrapulmonary comorbidities, treatment and outcome of eleven children with PIG were collected systematically. Results: 10/11 children presented with respiratory distress immediatly after birth and 8/11 needed invasive ventilation. In 8/11 children extrapulmonary comorbidities were present, congenital heart defects being the most common. 7/11 children received systemic glucocorticoids and of these four showed a clear favorable response. During a median follow-up of 3.0 years (range 0.42–12.0) one child died, while 10 patients improved. Chest CT-scans showed ground-glass opacities (7/10), consolidations (6/10), linear opacities (5/10) and mosaic attenuation (4/10) without uniform pattern. Besides interstitial thickening related to undifferentiated glycogen positive mesenchymal cells all tissue samples showed growth abnormalities with reduced alveolarization. Conclusions: PIG is associated with alveolar growth abnormalities and has to be considered in all newborns with unexplained respiratory distress. Apparent treatment benefit of glucocorticosteroids needs to be evaluated systematically.
AB - Background: Pulmonary interstitial glycogenosis (PIG) is a rare paediatric interstitial lung disease of unknown cause. The diagnosis can only be made by lung biopsy. Less than 100 cases have been reported. Clinical features, treatment and outcomes have rarely been assessed systematically in decent cohorts of patients. Methods: In this retrospective multicentre study, the clinical presentation, radiologic findings, pattern of lung biopsy, extrapulmonary comorbidities, treatment and outcome of eleven children with PIG were collected systematically. Results: 10/11 children presented with respiratory distress immediatly after birth and 8/11 needed invasive ventilation. In 8/11 children extrapulmonary comorbidities were present, congenital heart defects being the most common. 7/11 children received systemic glucocorticoids and of these four showed a clear favorable response. During a median follow-up of 3.0 years (range 0.42–12.0) one child died, while 10 patients improved. Chest CT-scans showed ground-glass opacities (7/10), consolidations (6/10), linear opacities (5/10) and mosaic attenuation (4/10) without uniform pattern. Besides interstitial thickening related to undifferentiated glycogen positive mesenchymal cells all tissue samples showed growth abnormalities with reduced alveolarization. Conclusions: PIG is associated with alveolar growth abnormalities and has to be considered in all newborns with unexplained respiratory distress. Apparent treatment benefit of glucocorticosteroids needs to be evaluated systematically.
KW - Biopsy
KW - Child
KW - Child, Preschool
KW - Drug Administration Schedule
KW - Female
KW - Gestational Age
KW - Glucocorticoids/administration & dosage
KW - Glycogen Storage Disease/diagnosis
KW - Humans
KW - Infant
KW - Lung Diseases, Interstitial/diagnosis
KW - Lung/pathology
KW - Male
KW - Rare Diseases/diagnosis
KW - Registries
KW - Retrospective Studies
KW - Tomography, X-Ray Computed
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047374681&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29957271
U2 - https://doi.org/10.1016/j.rmed.2018.05.009
DO - https://doi.org/10.1016/j.rmed.2018.05.009
M3 - Article
C2 - 29957271
SN - 0954-6111
VL - 140
SP - 11
EP - 20
JO - Respiratory Medicine
JF - Respiratory Medicine
ER -